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Abstract 
We have designed a pseudopolyrotaxane (PPRX), known as a molecular necklace, consisting of phenylboronic 
acid-modified γ-cyclodextrin (PBA-γ-CyD) and naphthalene-modified polyethylene glycol (Naph-PEG) for developing 
sugar-responsive insulin delivery systems. Interestingly, structural analyses show that the Naph-PEG/PBA-γ-CyD PPRX 
obtained by our method was single stranded, whereas ordinary PPRXs using parent γ-CyD were double stranded. The 
Naph-PEG/PBA-γ-CyD PPRX was poorly water soluble at pH 7.4; however, sugar addition induced disintegration of the 
PPRX, and the components were dissolved, suggesting that the PBA moiety acts as a sugar sensor. We also have 
developed a PPRX consisting of Naph-PEG-appended insulin (Naph-PEG-Ins) and PBA-γ-CyD and have confirmed that 
the release rate of Naph-PEG-Ins was accelerated following sugar addition. 
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Introduction  
 
One of the goals of drug delivery system is to control the timing and rate of drug release. Sustained drug release 
systems are one of the most successful time-controlled systems, and they have been applied to not only sustained-release 
oral tablets [1] but also long-acting injectable microspheres [2, 3] and transdermal sustained-release systems [4, 5]. There 
has recently been considerable interest in stimuli-sensitive drug delivery systems that can control the timing of drug 
release [6–8]. Such systems require the ability to recognize the surrounding environment of systems and the mechanism 
for drug release. For this purpose, cyclodextrin (CyD)-based molecular machines have attracted much attention [9, 10]. 
CyDs are cyclic oligosaccharides composed of glucopyranoside units. CyDs consist of a hydrophobic cavity in which 
hydrophobic molecules are enclosed to form an inclusion complex. CyDs include not only low molecular weight 
molecules but also polymers. The complexes in which many CyDs are threaded by a polymer are called 
pseudopolyrotaxanes (PPRXs) or polypseudorotaxanes. When both end groups of a polymer of PPRX are modified with 
bulky stoppers, the structures are called polyrotaxanes (PRXs). Harada et al. first reported that α-CyD forms a crystalline 
complex, with polyethylene glycol (PEG) in which PEG penetrated many cavities of α-CyD [11]. After their discovery, 
several combinations of CyD and polymers for PPRXs have been developed [12, 13]. The unique structures of PPRXs 
and PRXs have been applied for a new generation of drug delivery systems [14–24]. 
It is reasonable to use PEG for drug delivery systems because PEG itself is biocompatible and is approved as a 
pharmaceutical additive. Furthermore, PEGylation technologies have been widely used to improve therapeutic efficacies 
of some protein drugs, and some PEGylated proteins are in the market [25, 26]. Higashi et al. have prepared PPRXs 
composed of a PEGylated insulin (PEG-Ins) and α-CyD or γ-CyD [22–24]. Following subcutaneous administration of the 
PEG-Ins/CyD PPRX, the plasma levels of PEG-Ins in rats were significantly prolonged, achieving an extended 
hypoglycemic effect. The results suggest that the PEG-Ins/CyD PPRX can work as a sustained drug release system. 
However, the PEG-Ins/CyD PPRX was not designed to control the release rate of PEG-Ins, depending on the D-glucose 
(Glc) concentration. Sugar-responsive insulin (Ins) release systems are highly expected to increase the degree of freedom 
and convenience of use of self-injections for diabetic patients because Ins self-injection treatments are associated with 
difficulties concerning controlled blood sugar levels and risk of hypoglycemia. 
For developing sugar-responsive drug delivery systems, phenylboronic acid (PBA) constructs are promising. PBA 
reacts with cis-diol functional groups of sugars to form a five- or six-membered ring via ester bonds. As a result, PBA 
derivatives have been widely investigated as sugar-recognition motifs in chemical probes for sugar analysis [27–32] and 
sugar-sensitive Ins release systems [33–35]. We recently synthesized PBA-modified CyDs (PBA-CyDs) and found that 
they form supramolecular structures [36]. PBA-α-CyD formed a supramolecular polymer via head-to-tail interactions, 
whereas PBA-β-CyD formed a dimer via head-to-head interactions. The resulting supramolecular structures showed low 
solubility in water; however, the addition of sugar induced an increase in their solubility. These results suggest a new 
approach to chemical-responsive materials on the basis of the use of guest-modified CyDs. To progress to the next stage, 
we must develop a construct that combines the supramolecular structures using PBA-CyDs and Ins. 
PBA-γ-CyD does not form a poorly-soluble supramolecular structure by itself because the γ-CyD cavity is too large 
to include the PBA moiety. On the basis of the idea that the large cavity of PBA-γ-CyD may be suitable for the inclusion 
of PEG chains, we combined PBA-γ-CyD and PEG-Ins in a PPRX. The building blocks for PPRXs are shown in Fig. 1. 
Naphthalene-modified PEG (Naph-PEG) was used because our preliminary experiments revealed that Naph-PEG was 
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more effective in forming PPRXs compared with unmodified PEG. We investigated the resulting PPRX composed of 
Naph-PEG and PBA-γ-CyD (Naph-PEG/PBA-γ-CyD) to identify both its structure and sugar response. Then, we applied 
the PPRX system to Naph-PEG-appended Ins (Naph-PEG-Ins) to fabricate a new type of sugar-responsive Ins release 
system (Fig. 2). 
 
Experimental  
 
Materials 
 
γ-CyD was obtained from Junsei Chemical Co., Ltd. (Tokyo, Japan). Polyethylene glycol (MW 2000), 
p-chlorocarbonylphenylboronic acid, and Ins (human, recombinant) were purchased from Wako Pure Chemical Industries 
(Osaka, Japan). 2-Naphthoyl chloride and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) were 
obtained from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). 2-[4-(2-Hydroxyethyl)-1-piperazinyl] ethanesulfonic 
acid (HEPES) was purchased from Dojindo Laboratories (Kumamoto, Japan). Sunbright PA-020HC 
[H2N-(CH2)3-O-PEG-(CH2)5-COOH, MW 2000] was obtained from NOF Corporation (Tokyo, Japan). All other 
chemicals were of reagent grade and were used as received.  
 
Apparatus 
 
1H NMR measurements were conducted with a Varian 400-MR (Agilent Technologies, California, USA). Solid-state 
fluorescence spectroscopy was performed with RF-5300PC spectrofluorophotometer (Shimadzu Corporation, Kyoto, 
Japan). Turbidity was monitored with a V-530 UV–vis spectrometer (JASCO Corporation, Tokyo, Japan) using 
absorbance at 700 nm. The release rate of Naph-PEG was monitored using a Spectra Max M5e multiplate reader 
(Molecular Devices Japan, Tokyo, Japan). Differential scanning calorimetry (DSC) was carried out using a Thermo Plus2 
series (Rigaku Corporation, Tokyo, Japan). A sample was heated in an aluminum pan at a heating rate of 5 K/min under a 
nitrogen atmosphere. Powder X-ray diffraction patterns were measured using a Mini FlexII (Rigaku Corporation, Tokyo, 
Japan) under the following conditions: We used CuKα radiation, and diffraction was done at 30 kV, 15 mA with a 
scanning speed of 4°/min and measurement range of 2θ = 3°–40°. MALDI-TOF MS spectra were recorded with 
AXIMA-CFR plus (Shimadzu). 
 
Synthesis 
 
Phenylboronic acid-modified γ-cyclodextrin (PBA-γ-CyD) 
 
γ-CyD (2.61 g, 2.00 mmol) was dried under reduced pressured for 4 h at 100°C, and it was dissolved into anhydrous 
pyridine (200 mL). p-Chlorocarbonylphenylboronic acid (1.00 g, 5.43 mmol) was added to the solution. The solution was 
stirred at 90°C, and it was check to with silikagel TLC (Eluent, n-BtOH:EtOH:H2O = 5:4:3 in volume ratio, Coloring 
with anisaldehyde). After di-modified PBA-γ-CyD appeared, the reaction was stopped by the addition of small amount of 
water. The reaction solution was evaporated to concentrate, 40 mL of the concentrated solution was added to 400 mL of 
acetone, and the precipitate was filtered using a glass filter. The white powder was dissolved in 200 mL of water, and the 
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solution was filtered to remove insoluble matter. The filtrate was applied to column chromatography using a highly 
porous polystyrene gel (Diaion HP-20, Mitsubishi Chemical, Japan). The mixed solution of H2O and MeOH was used as 
an eluent. When the volume ratio of MeOH:H2O was 1:1, the mono modified PBA-γ-CyD was eluted. The eluates 
containing PBA-γ-CyD were gathered and were evaporated to concentrate. Forty mL of the concentrated solution was 
added to 400 mL of acetone, and the precipitate was filtered using a glass filter. The white powder was washed with 
acetone three times and was dried in vacuo (0.449 g, 15.5%). 
1H NMR (400 MHz, DMSO-d6, Fig. S1) δ 8.25 (s, 2H, BOH), 7.97–7.79 (m, 4H, ArH), 5.99–5.56 (m, 16H, CyD OH-2, 
OH-3), 4.97–4.80 (m, 8H, CyD H-1), 4.59–4.41 (m, 7H, CyD OH-6), 3.73–3.40 (m, 32H, CyD H-3, H-5, H-6a, b) 3.37–
3.25 (m, overlaps with HOD).  
FAB-MS, negative mode, matrix: glycerol m/z: 1499.5 [(M + glycerol - 2H2O - H)− requires 1499.5]. The PBA-γ-CyD 
was detected as an ester form composed of PBA-γ-CyD and glycerol. 
Anal. Calcd for C55H85BO43 + 6H2O: C, 42.53; H, 6.29; B, 0.70; O, 50.48. Found: C, 42.37; H, 6.06. 
 
Naphthalene-modified polyethylene glycol (Naph-PEG) 
 
PEG (MW 2000, 10.0 g) was dissolved in a mixed solution of anhydrous dichloromethane (300 mL) and anhydrous 
pyridine (22.5 mL). The solution was stirred at 0°C, and 2-naphthoyl chloride (6.4 g, 34 mmol) was added to the solution. 
It was stirred at 0°C under a nitrogen atmosphere for 3 days. A small amount of water was added to stop the reaction, and 
the solution was filtered with a glass filter to remove insoluble matter. The filtrate was evaporated, and the residue was 
recrystallized with EtOH. 
1H NMR (400 MHz, D2O, Fig. S2) δ 8.37–8.61 (s, 1H, Naphthoyl H-1), 7.80–7.63 (m, 4H, Naphthoyl H-3, H-4, H-5, 
H-8), 7.50–7.35 (m, 2H, Naphthoyl H-6, H-7), 4.38–4.23 (m, 2H, Carbonyl α-H), 3.54–3.45 [m, 85H, -(CH2-CH2-O)n-]. 
MALDI-TOF MS m/z: 2466.70 [M + H]+. 
 
One-terminal naphthalene-modified polyethylene glycol (One-Naph-PEG) 
 
H2N-(CH2)3-O-PEG-(CH2)5-COOH (MW 2000, 300 mg) was dissolved in a mixed solution of anhydrous 
dichloromethane (10 mL) and anhydrous pyridine (0.70 mL). The solution was stirred at 0°C, and 2-naphthoyl chloride 
(286 mg, 1.50 mmol) was added to the solution. It was stirred at 0°C under a nitrogen atmosphere for 4 days. The solvent 
was evaporated, and water (40 mL) was added to the residue. The solution was filtered with glass filter to remove 
insoluble matter, and the filtrate was dialyzed against water using a dialysis tube (MWCO 1000). The resulting solution 
was lyophilized, and One-Naph-PEG was obtained (229 mg, 69.3 %) 
1H NMR (400 MHz, D2O, Fig. S3) δ 8.22–8.16 (s, 1H, Naphthoyl H-1), 7.93–7.81 (m, 3H, Naphthoyl H-3, H-4, H-5), 
7.69–7.64 (d, 1H, Naphthoyl H-8), 7.55–7.45 (m, 2H, Naphthoyl H-6, H-7), 3.72–3.66 (m, 2H, α-H of the amide group), 
3.53–3.51 [m, 187H, -(CH2-CH2-O)n-], 2.03–1.97 (t, 2H, α-H of the carboxyl group), 1.82–1.74 (m, 2H, alkyl), 1.65–1.56 
(m, 2H, alkyl), 1.47–1.34 (m, 8H, alkyl). 
MALDI-TOF MS m/z: 2394.46 [M + H]+. 
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Naph-PEG-appended Ins (Naph-PEG-Ins) 
 
Ins (208 mg, 48.2 μmol) and One-Naph-PEG (0.208 g, 96.3 μmol) were dissolved in DMSO (28 mL), and EDC (18.0 
mg, 96.3 μmol) was added. The solution was stirred at room temperature for 48 h, and water (80 mL) was added. The 
solution was dialyzed against water using a dialysis tube (MWCO 3500). The resulting solution was lyophilized, and 
Naph-PEG-Ins was obtained (348 mg, 66.3%). The stoichiometry of PEG/Ins in the Naph-PEG-Ins was calculated to be 
2.2. The details are described in the Supplementary Data (Figs. S4 and S5). 
 
Preparation of PPRXs 
 
Naph-PEG/PBA-γ-CyD PPRX 
 
Naph-PEG (12.3 mg, 5.5 μmol) and PBA-γ-CyD (100 mg, 69.2 μmol) were dissolved in water (500 μL), and the 
solution was kept at room temperature. After 28 days, the resulting precipitate of the PPRX was filtered and dried under 
reduced pressure (84.7 mg). The Naph-PEG/PBA-γ-CyD PPRX was obtained as a crystalline precipitate but not a gel 
(Fig. S6). The Naph-PEG/PBA-γ-CyD PPRX was dissolved in DMSO-d6 and measured with 1H NMR (Fig. S7). When 
the integration of H-1 of CyD was set to be 8.00, the integration of the PEG part was 8.10. From this result, we calculated 
the stoichiometry between the ethylene glycol monomer unit and PBA-γ-CyD to be 2.1:1.0. 
 
Naph-PEG-Ins/PBA-γ-CyD PPRX 
 
Naph-PEG-Ins (33.4 mg, 30.8 μmol) and PBA-γ-CyD (200 mg, 138.4 μmol) were dissolved in water (1000 μL), and 
the solution was kept at room temperature. After 28 days, the resulting precipitate of the PPRX was filtered and dried 
under reduced pressure (117.2 mg). The Naph-PEG-Ins/PBA-γ-CyD PPRX was formed as a crystalline precipitate but 
not a gel (Fig. S8). The Naph-PEG/PBA-γ-CyD PPRX was dissolved in DMSO-d6 and measured with 1H NMR (Fig. S9). 
When the integration of H-1 of CyD was set to be 8.00, the integration of the PEG part was 9.38. From this result, we 
calculated the stoichiometry between the ethylene glycol monomer unit and PBA-γ-CyD to be 1.4:1.0. 
 
Evaluation of sugar responsiveness of PPRXs 
 
Turbidity measurements 
 
A buffer solution (20 mM HEPES, pH 7.4, 2.0 mL) was added to a cell for absorption spectrometer, and the buffer 
solution was kept at 37°C and stirred. The Naph-PEG/PBA-γ-CyD PPRX (6.0 mg) was suspended in the stirred buffer 
solution, and the turbidity was measured by absorbance at 700 nm. After the turbidity became constant, a small amount 
of stock sugar solution (1.00 M) was added at 10-min intervals to the suspended solution to increase the sugar 
concentration. 
 
Release tests of PEG chains using fluorescence of the naphthoyl moiety 
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A buffer solution with and without sugars (20 mM HEPES, pH 7.4, 1.0 mL) was added to a microtube for 
centrifugation, and the buffer solution was kept at 37°C. A PPRX (Naph-PEG/PBA-γ-CyD PPRX: 3.0 mg, 
Naph-PEG-Ins/PBA-γ-CyD PPRX: 6.0 mg) was added to the solution. After a certain time, the microtube was 
centrifuged, and the small amount of supernatant was collected. The fluorescence derived from the naphthoyl moiety was 
monitored with a microplate reader (λex = 280 nm, λem = 420 nm). 
 
Results and discussion 
 
Preparation of the Naph-PEG/PBA-γ-CyD PPRX 
 
The synthesized mono modified PBA-γ-CyD shows high solubility (>100 mM), similar to parent γ-CyD, which is 
suitable for the preparation of PPRXs. In contrast, PBA-α-CyD and PBA-β-CyD shows low solubility because of the 
formation of supramolecular structures [36]. In a preliminary experiment, we used unmodified PEG to prepare a PPRX. 
PEG (MW 2000, 11.0 mg, 5.50 μmol) and PBA-γ-CyD (100 mg, 69.2 μmol) were dissolved in water (500 μL), and the 
solution was kept at room temperature, but there was no precipitate. Then, the solution was kept at 60°C. After 28 days, 
the resulting precipitate of the PPRX was filtered and dried under reduced pressure (55.0 mg). We considered that 
temperature of 60°C is too high to apply to protein drugs and realized that the modification of the terminal of PEG was 
effective to form PPRXs [12]. We modified both of the terminal hydroxyl groups of PEG with naphthoyl groups 
(Naph-PEG) and used the latter to prepare a PPRX. Naph-PEG (12.3 mg, 5.50 μmol) and PBA-γ-CyD (100 mg, 69.2 
μmol) were dissolved in water (500 μL), and the solution was kept at room temperature. After 28 days, the resulting 
precipitates, which we considered to be a PPRX, were filtered and dried under reduced pressure (84.7 mg). 
 
Structural analysis of the Naph-PEG/PBA-γ-CyD PPRX 
 
To clarify whether or not PBA-γ-CyD includes Naph-PEG in the resulting precipitate, we measured it with DSC (Fig. 
3) and XRD (Fig. 4). In the DSC thermograms of Naph-PEG, an endothermic peak was observed at 39°C, corresponding 
the melting point of Naph-PEG. In the DSC thermograms of the Naph-PEG/PBA-γ-CD PPRX, the endothermic peak 
disappeared completely, which demonstrates that Naph-PEG is fully included in the cavities of γ-CyD [21].  
The XRD pattern of the Naph-PEG/PBA-γ-CyD PPRX was highly crystalline, which supports the formation of 
PPRXs. However, the pattern was quite different from that of PPRXs using parent γ-CyD [20], suggesting that the 
obtained precipitate is a new type of PPRX. To investigate the stoichiometry, we dissolved the Naph-PEG/PBA-γ-CyD 
PPRX in DMSO-d6 and measured results using 1H NMR. The spectra showed that the stoichiometry between the 
ethylene glycol monomer unit and PBA-γ-CyD was 2:1. This value is similar to that of a PEG/α-CyD PPRX but not to 
that of a PEG/γ-CyD PPRX. The PEG/α-CyD PPRX is single stranded, and the stoichiometry between its ethylene glycol 
monomer unit and PBA-γ-CyD is 2:1 [11]. In contrast, the PEG/γ-CyD PPRX is double stranded, and its stoichiometry 
between the ethylene glycol monomer unit and PBA-γ-CyD is 4:1 [12]. This result implies the formation of a 
single-stranded PPRX composed of Naph-PEG and PBA-γ-CyD. 
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Fluorescence spectroscopy of the naphthoyl group at the terminal PEG chain provides information about whether the 
PPRX is single stranded or double stranded [12]. We monitored the solid-state fluorescence spectra of the 
Naph-PEG/PBA-γ-CyD PPRX and compared these spectra with those of the PPRX composed of Naph-PEG and parent 
CyDs (Fig. 5). The spectrum of Naph-PEG/γ-CyD shows an excimer emission that is widened and shifted to a longer 
wavelength, which means that two naphthoyl groups were included within the cavity of the parent γ-CyD. This 
appearance of excimer emission proves that the Naph-PEG/γ-CyD PPRX has double-stranded PEG chains. In contrast, 
the spectrum of the Naph-PEG/PBA-γ-CyD PPRX shows a peak at 363 nm derived from a monomeric naphthoyl group, 
indicating the formation of a single-stranded PPRX like the Naph-PEG/α-CyD PPRX. From the results of 1H NMR and 
solid-state fluorescence spectroscopy, we conclude that the Naph-PEG/PBA-γ-CyD PPRX is single stranded. The 
formation of single-stranded PPRX with a guest-modified γ-CyD has never been reported before.  
To gain an insight into the intermolecular interactions between building blocks, we measured the NMR spectra of 
PBA-γ-CyD in the dissolved state. The two-dimensional nuclear Overhauser effect spectroscopy (NOESY) spectrum of a 
solution containing PBA-γ-CyD (5.0 mM) in D2O showed the nuclear Overhauser effect (NOE) interaction between the 
protons of the phenyl group and the interior protons of the CyD’s cavity (H-3 and H-5, Fig. S10), indicating that the PBA 
moiety was included by the CyD moiety. The one-dimensional 1H NMR spectra of PBA-γ-CyD in D2O showed that the 
protons of the phenyl ring shifted as the concentration of PBA-γ-CyD increased (Fig. S11), indicating that the interaction 
of PBA and CyD ring is intermolecular but not intramolecular [37].  
To investigate the spatial arrangement of Naph-PEG, we measured the rotating Overhauser enhancement and 
exchange spectroscopy (ROESY) spectrum of a solution containing Naph-PEG (0.4 mM) and PBA-γ-CyD (2.0 mM) in 
D2O. In the spectrum, the NOE interaction between the protons of the phenyl group and the protons of the PEG moiety 
(Fig. S12) demonstrate that the PBA moiety and the PEG chain are present nearby.  
To summarize these NMR results, a single-stranded PEG is included by the γ-CyD ring, and the remaining space is 
occupied by the PBA moiety because the single PEG chain is not sufficiently large to occupy the large cavity of γ-CyD. 
  
Sugar response of the Naph-PEG/PBA-γ-CyD PPRX 
 
We evaluated the sugar responses of the Naph-PEG/PBA-γ-CyD PPRX with respect to the solubility changes using 
turbidity measurement (Fig. 6) and change in the release rate of Naph-PEG by monitoring the fluorescence of terminal 
naphthoyl groups of PEG chains (Fig. 7). Naph-PEG/PBA-γ-CyD (6.0 mg) was suspended in a buffer solution (2.0 mL, 
20 mM HEPES buffer pH 7.4, 37°C). After the turbidity became constant, stock sugar solution was added to the 
suspended solution. The turbidity was decreased as the concentration of sugar increased, which suggests that the solid 
structure of the PPRX disintegrates and dissolves because of the effect of sugar. The effect of D-fructose (Fru) was larger 
than that of Glc, proving that the PBA moiety acts as a sugar-recognition moiety because PBA reacts more strongly with 
Fru than with Glc [27–30]. 
Fig. 7 shows the release rate of Naph-PEG in various conditions. The sugar addition accelerated the rate, which 
depends on the kind and concentration of sugars. These results show that we have successfully introduced sugar 
responsiveness into the PPRX for the first time; however, it is not sufficient for controlled release of Ins. About 10% of 
Naph-PEG was released after 8 h, indicating that the PPRX is disintegrated in water by dilution. Although an ideal 
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system has a clear on/off response for sugar, the current system shows a slow release of Naph-PEG in the absence of 
sugar. The PPRX should be more rigid in the absence of sugar. The structure of building blocks, polymer and modified 
CyD, and their combination can affect the rigidity of the PPRX. At the same time, the PPRX should have a 
transformability that would be influenced by affinities of the PBA moiety for Glc and by the spatial arrangement of 
building blocks. The balance between rigidity and transformability are important and will be the focus of our future 
work. 
 
Preparation of Naph-PEG-Ins/PBA-γ-CyD PPRX  
 
We prepared Naph-PEG-Ins using heterobifunctional PEG [H2N-(CH2)3-O-PEG-(CH2)5-COOH]. The amine end was 
modified with a naphthoyl group, and the carboxylic terminal was linked to amino groups of Ins (Fig. 1). The average 
ratio between PEG and Ins was calculated to be 2.2 from 1H NMR spectra of Naph-PEG-Ins (Figs. S4 and S5). A 
solution of Naph-PEG-Ins was added to a solution of PBA-γ-CyD, and a Naph-PEG-Ins/PBA-γ-CyD PPRX was formed 
as a crystalline precipitate (Fig. S8). The results of 1H NMR (Fig. S9), DSC (Fig. S13), and XRD (Fig. S14) were similar 
to those of the Naph-PEG/PBA-γ-CyD PPRX, indicating the Naph-PEG-Ins/PBA-γ-CyD PPRX was successfully 
obtained. 
 
Sugar response of the Naph-PEG-Ins/PBA-γ-CyD PPRX 
 
We investigated the effect of sugar on the release of Naph-PEG-Ins from the Naph-PEG-Ins/PBA-γ-CyD PPRX. The 
suspension of Naph-PEG-Ins/PBA-γ-CyD PPRX was kept at 37°C, and the amount of Naph-PEG-Ins dissolved into 
supernatant was evaluated by monitoring the fluorescence of the terminal naphthoyl group of Naph-PEG-Ins. Fig. 8 
shows that the release rate is accelerated in the presence of sugar, and the release rate depends on the kind and 
concentrations of sugars.  
Current guidelines recommend a post-meal Glc level of < 10 mM and a fasting plasma Glc level of 3.9–7.2 mM [38]. 
Compared with the blood Glc level, the PPRX system requires a higher concentration of Glc. Our next challenge is to 
increase the Glc affinity of the PBA moiety. The PBA derivatives employed here are the simplest structures and showed a 
relatively low affinity for Glc. At present, there are many PBA-based Glc sensors that show a high affinity for Glc [39–
41]. For example, a fluorescent sugar sensor containing bis-boronic acid shows an elevated affinity that includes a 
clinically meaningful Glc level [41]. The introduction of a sophisticated bis-boronic acid derivative to the CyD ring 
perhaps would be a suitable system.  
 
Conclusion 
We have successfully developed a new model of a stimuli-responsive PPRX. The Naph-PEG/PBA-γ-CyD PPRX was 
insoluble in a pH 7.4 solution; however, sugar addition induced disintegration of the PPRX. This model is applicable to 
PEG-Ins, and we demonstrated that the release rate of Naph-PEG-Ins was accelerated in the presence of sugar. It is 
worthy of attention that the Naph-PEG-Ins/PBA-γ-CyD PPRX works as a sugar responsive release system, in which Glc 
triggers the disintegration of the PPRX and the accompanying release of Naph-PEG-Ins. In other words, this is the first 
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successful attempt to introduce a sugar responsiveness into PEG-Ins/CyD PPRXs that have been developed as a sustained 
release system for PEG-Ins [22–24]. 
In this study, we also discovered that PPRXs using PBA-γ-CyD were single stranded despite the large cavity of 
γ-CyD. We demonstrated that the non-covalent molecular interaction between a PBA moiety and a CyD cavity is 
important to form a single-stranded PPRX. In further studies, we must increase the affinity of PBA derivatives for Glc. 
To address this issue, we will attempt to introduce various PBA derivatives into the γ-CyD ring. 
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Fig. 1. Chemical structures of building blocks of sugar-responsive PPRXs. 
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 Fig. 2. Schematic illustration of sugar-induced disintegration of Naph-PEG-Ins/PBA-γ-CyD PPRX. 
 
Fig. 3. DSC thermograms: (a) PBA-γ-CyD, (b) Naph-PEG, (c) physical mixture of Naph-PEG and PBA-γ-CyD, and (d) 
Naph-PEG/PBA-γ-CyD PPRX. 
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 Fig. 4. XRD patterns: (a) PBA-γ-CyD, (b) Naph-PEG, (c) physical mixture of Naph-PEG and PBA-γ-CyD, and (d) 
Naph-PEG/PBA-γ-CyD PPRX. 
  
Fig. 5. Solid-state fluorescence spectra of Naph-PEG with α-CyD, γ-CyD, or PBA-γ-CyD. 
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 Fig. 6. The turbidity change of the Naph-PEG/PBA-γ-CyD PPRX depending on the sugar concentration (pH 7.4, 37°C). 
 
  
Fig. 7. Release profiles of Naph-PEG from the Naph-PEG/PBA-γ-CyD PPRX in the absence and presence of sugars (pH 
7.4, 37 °C). 
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 Fig. 8. Release profiles of Naph-PEG-Ins from the Naph-PEG-Ins/PBA-γ-CyD PPRX in the absence and presence of 
sugars (pH 7.4, 37°C). 
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1. NMR spectra 
(1) Phenylboronic acid modified γ-CyD (PBA-γ-CyD) 
 
Fig. S1. The 1H NMR spectrum of PBA-γ-CyD in DMSO-d6 at 25°C.  
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(2) Naphthalene-modified polyethylene glycol (Naph-PEG) 
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Fig. S2. The 1H NMR spectrum of Naph-PEG in D2O at 25°C. 
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(3) One terminal naphthalene-modified polyethylene glycol (One-Naph-PEG) 
  
Fig. S3. The 1H NMR spectrum of One-Naph-PEG in D2O at 25°C. 
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(4) Naph-PEG-appended insulin (Naph-PEG-Ins) 
 
Fig. S4. The 1H NMR spectrum of Naph-PEG-Ins in DMSO-d6 at 25°C, and the enlarged views of signals at 0.7-09 
ppm and 3.5 ppm. 
 
In order to evaluate the stoichiometry of PEG/Ins in the obtained 
Naph-PEG-Ins, DMSO-d6 solutions containing PEG and Ins with 
various molar ratio (0.0, 1.0, 1.5, 3.0, 6.0, 12.0), and they were 
measured with 1H NMR. The integrated intensity of the signals at 
0.7-0.9 ppm derived from insulin and that at integration of the 
signal of PEG at 3.5 ppm was evaluated. The PEG/Ins intensity 
ratio was plotted against PEG/Ins molar ratio to obtain linear 
standard curve. When Naph-PEG-Ins was dissolved in DMSO-d6 
and monitored with 1H NMR, the PEG/Ins intensity ratio was 5.5, 
which means the PEG/Ins molar ratio is 2.2 in Naph-PEG-Ins.                                                       
                                                         
Fig. S5. The liner standard curve for PEG/Ins ratio. 
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 (5) Naph-PEG/PBA-γ-CyD PPRX 
 
Fig. S6. An optical micrograph of Naph-PEG/PBA-γ-CyD PPRX. 
 
 
 
Fig. S7. The 1H NMR spectrum of Naph-PEG/PBA-γ-CyD PPRX in DMSO-d6 at 25°C. 
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(6) Naph-PEG-Ins/PBA-γ-CyD PPRX 
 
Fig. S8. An optical micrograph of Naph-PEG-Ins/PBA-γ-CyD PPRX. 
 
Fig. S9. The 1H NMR spectrum of Naph-PEG-Ins/PBA-γ-CyD PPRX in DMSO-d6 at 25°C. 
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(7) NOESY spectrum of PBA-γ-CyD 
 
 
  
Fig. S10. The 1H-1H NOESY spectrum of PBA-γ-CyD 5.0 mM in D2O at 25oC with mixing time of 200 ms and its 
proposed structures. 
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(8) PBA-γ-CyD in various concentrations 
 
 
Fig. S11. The 1H NMR spectral changes of PBA moiety depending on the concentration of PBA-γ-CyD (0.5, 1.0, 
2.0, 5.0 and 10.0 mM) in D2O at 25°C. 
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(9) ROESY spectrum of PBA-γ-CyD with Naph-PEG 
 
 
   
 
Fig. S12. The 1H-1H ROESY spectrum of PBA-γ-CyD 2.0 mM with Naph-PEG 0.4 mM in D2O at 25oC with 
mixing time of 200 ms and its proposed structures. 
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2. DSC thermograms 
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Fig. S13. DSC thermograms: (a) PBA-γ-CyD, (b) Naph-PEG-Ins, (c) physical mixture of 
Naph-PEG-Ins and PBA-γ-CyD, and (d) Naph-PEG-Ins/PBA-γ-CyD PPRX. 
 
3. XRD patterns of Naph-PEG-Ins/PBA-γ-CyD PPRX 
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Fig. S14. XRD patterns: (a) PBA-γ-CyD, (b) Naph-PEG-Ins, (c) physical mixture of Naph-PEG-Ins 
and PBA-γ-CyD, and (d) Naph-PEG-Ins/PBA-γ-CyD PPRX. 
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